For these reasons, risk stratification of TTR-CA patients is imperative in order to identify patients with at risk of a faster disease progression towards HF, as this subset requires earlier and more aggressive therapies, as well as closer monitoring. This evidence concerns the gene TTR and hydrops fetalis.